|
| Full Name | Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B |
| Chromosome | 19p13.12 |
| NCBI Gene ID | 9149 |
| Ensembl ID | ENSG00000105204 |
| OMIM ID | 604556 |
| UniProt ID | Q9Y463 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [PSP](/diseases/psp), Metabolic Syndrome, Tauopathies |
DYRK1B (also known as MIRK — Minibrain-Related Kinase) encodes a dual-specificity protein kinase belonging to the DYRK family, which phosphorylates substrates on both serine/threonine and tyrosine residues. DYRK1B is the closest paralog of DYRK1A, one of the most important kinases in Down syndrome-associated Alzheimer's disease. While DYRK1A has been extensively studied for its role in tau hyperphosphorylation and amyloid processing, DYRK1B has received less attention despite sharing key substrate specificities and potentially contributing to tauopathy through complementary mechanisms.
DYRK1B is expressed in the brain and is catalytically active at the time of translation through an intramolecular autophosphorylation mechanism. Its activation of quiescence programs, roles in GSK-3β signaling, and direct tau phosphorylation activity make it relevant to neurodegenerative disease — particularly progressive supranuclear palsy (PSP) and other primary tauopathies where tau kinase inhibition is an active therapeutic strategy.
¶ Gene Structure and Expression
DYRK1B is located on chromosome 19p13.12 and encodes a 629-amino acid protein kinase. The protein contains:
- N-terminal DYRK homology (DH) box (residues 70-88): Unique to the DYRK family, required for proper folding and activation
- Kinase domain (residues 112-445): Catalytic domain with dual-specificity activity. Contains the characteristic YxY motif in the activation loop — the second tyrosine (Y273) undergoes autophosphorylation during translation, which is required for kinase activation
- PEST domain (residues 481-580): Contains PEST sequences that regulate protein turnover
- C-terminal region: Contains a nuclear localization signal and regulatory domains
DYRK1B expression in the adult brain is moderate compared to DYRK1A, with highest levels in the hippocampus, cerebral cortex, and cerebellum. Unlike DYRK1A, DYRK1B expression is enriched in quiescent cells and non-dividing neurons, consistent with its role in promoting G0 arrest and cellular quiescence.
¶ Kinase Activity and Substrate Specificity
DYRK1B is a proline-directed kinase with substrates overlapping those of DYRK1A:
- Tau phosphorylation: DYRK1B directly phosphorylates tau at multiple sites including Thr212, which primes tau for subsequent GSK-3β-mediated phosphorylation at Ser208 — a critical step in generating the pathological AT8 and PHF-1 epitopes characteristic of tauopathy
- Cyclin D1: Phosphorylation of cyclin D1 at Thr286, targeting it for nuclear export and proteasomal degradation, enforcing cell cycle exit
- p27Kip1: Stabilization of the CDK inhibitor p27, maintaining quiescence
- DREAM complex: Phosphorylation of LIN52 at Ser28, promoting DREAM complex assembly and transcriptional repression of cell cycle genes
¶ Cell Cycle Regulation and Quiescence
DYRK1B's primary physiological function involves maintaining cellular quiescence:
- G0 maintenance: DYRK1B promotes entry into and maintenance of G0 quiescence in differentiated cells, including neurons
- Anti-proliferative signaling: Through cyclin D1 degradation and p27 stabilization
- Aberrant cell cycle re-entry prevention: In post-mitotic neurons, DYRK1B helps prevent pathological cell cycle re-entry, which has been implicated as a death pathway in Alzheimer's disease
DYRK1B has significant metabolic functions:
- Hedgehog signaling: DYRK1B promotes GLI1 nuclear import, activating Hedgehog target genes
- mTOR pathway: DYRK1B can modulate mTOR signaling through effects on upstream regulators
- Lipid metabolism: Gain-of-function DYRK1B mutations cause familial metabolic syndrome (AOMS3), linking kinase hyperactivity to metabolic disease
A critical function in neurodegeneration:
- Priming kinase: DYRK1B phosphorylates tau at sites that prime subsequent phosphorylation by GSK-3β, the most important tau kinase
- Synergistic hyperphosphorylation: The DYRK1B → GSK-3β sequential phosphorylation cascade generates heavily phosphorylated tau species that are prone to aggregation into paired helical filaments (PHFs)
- Functional redundancy with DYRK1A: DYRK1B may partially compensate when DYRK1A is inhibited, posing a challenge for tau kinase-targeted therapeutics
DYRK1B contributes to AD pathogenesis through several mechanisms:
- Tau hyperphosphorylation: Direct phosphorylation of tau and priming for GSK-3β creates the pathological tau species that form neurofibrillary tangles
- Cell cycle re-entry: Loss of DYRK1B-mediated quiescence may allow aberrant cell cycle re-entry in neurons, a process observed in AD brains that precedes neuronal death
- RCAN1 regulation: DYRK1B, like DYRK1A, can phosphorylate RCAN1 (Regulator of Calcineurin 1), modulating calcineurin-NFAT signaling in neurons
- Compensatory upregulation: When DYRK1A inhibitors are tested therapeutically, DYRK1B may be upregulated as a compensatory tau kinase, potentially limiting treatment efficacy
¶ Progressive Supranuclear Palsy and Tauopathies
DYRK1B is relevant to primary tauopathies:
- 4R-tau phosphorylation: PSP and corticobasal degeneration are characterized by 4R-tau pathology. DYRK1B's tau phosphorylation activity is relevant to the tau isoform composition in these diseases
- MAPT H1 haplotype: PSP is strongly associated with the MAPT H1 haplotype, which increases tau expression. DYRK1B-mediated phosphorylation of this excess tau may contribute to disease
- Brainstem vulnerability: DYRK1B expression in brainstem nuclei vulnerable in PSP (substantia nigra, subthalamic nucleus, pontine tegmentum) positions it as a contributor to regional tau pathology
- Therapeutic target: Pan-DYRK inhibitors (targeting both DYRK1A and DYRK1B) may be more effective than DYRK1A-selective inhibitors for tauopathy treatment
Gain-of-function mutations in DYRK1B cause autosomal dominant metabolic syndrome type 3 (OMIM #615812):
- R102C mutation: Activating mutation causing central obesity, type 2 diabetes, hypertension, and coronary artery disease
- H90P mutation: Another activating mutation with similar metabolic phenotype
- Brain-body axis: The metabolic syndrome phenotype raises questions about whether DYRK1B hyperactivity in the brain could contribute to metabolic risk factors for neurodegeneration
- Pan-DYRK inhibitors: Compounds such as harmine, INDY, leucettine L41, and AZ191 inhibit both DYRK1A and DYRK1B. Dual inhibition may be necessary to prevent compensatory tau phosphorylation
- DYRK1B-selective inhibitors: AZ191 shows some selectivity for DYRK1B over DYRK1A, enabling studies of DYRK1B-specific functions
- Combination strategies: DYRK1B inhibition combined with GSK-3β inhibition (e.g., tideglusib) could block the sequential priming cascade more effectively
- PROTAC approach: Targeted protein degradation of DYRK1B using PROTAC technology is under investigation
- Kinase selectivity: The DYRK family shares high kinase domain similarity, making isoform-selective inhibition difficult
- Metabolic side effects: DYRK1B inhibition could potentially cause metabolic derangements given its role in glucose and lipid metabolism
- Compensatory mechanisms: Other proline-directed kinases (CDK5, CLK1) may compensate for DYRK1B loss
- Lochhead et al. (2005) elucidated the DYRK family activation mechanism through co-translational autophosphorylation
- Keramati et al. (2014) identified gain-of-function DYRK1B mutations causing metabolic syndrome
- Ashford et al. (2014) characterized DYRK1B's role in the DREAM complex and transcriptional repression
- Ferrer et al. (2005) demonstrated DYRK1A/1B overexpression in tauopathy-affected brain regions